Daridorexant

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

5 API Suppliers, 5 Listed Suppliers

DEVELOPMENTS

21 Drug(s) in Development

21 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports

DOSSIERs // Finished Dosage Formulations

2 Dossiers, 2 FDA Orange Book

MARKET PLACE

2 APIs

2 APIs

PATENTS

6 US Patents, 2 US Exclusivities

DIGITAL CONTENT

31 News

31 News

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

44,616

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Daridorexant, 1505484-82-1, Act-541468, Quviviq, Daridorexant [usan], Lmq24g57e9

Molecular Formula

C₂₃H₂₃ClN₆O₂

Molecular Weight

450.9 g/mol

InChI Key

NBGABHGMJVIVBW-QHCPKHFHSA-N

FDA UNII

LMQ24G57E9

Nemorexant is under investigation in clinical trial NCT03101189 (A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects).

Daridorexant is an Orexin Receptor Antagonist. The mechanism of action of daridorexant is as an Orexin Receptor Antagonist.

1 2D Structure

Daridorexant

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

[(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone

2.1.2 InChI

InChI=1S/C23H23ClN6O2/c1-14-17(24)6-7-18-20(14)28-22(27-18)23(2)9-4-12-29(23)21(31)16-13-15(32-3)5-8-19(16)30-25-10-11-26-30/h5-8,10-11,13H,4,9,12H2,1-3H3,(H,27,28)/t23-/m0/s1

2.1.3 InChI Key

NBGABHGMJVIVBW-QHCPKHFHSA-N

2.1.4 Canonical SMILES

CC1=C(C=CC2=C1N=C(N2)C3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl

2.1.5 Isomeric SMILES

CC1=C(C=CC2=C1N=C(N2)[C@@]3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl

2.2 Other Identifiers

2.2.1 UNII

LMQ24G57E9

2.3 Synonyms

2.3.1 MeSH Synonyms

1. ((s)-(2-(5-chloro-4-methyl-1h-benzo(d)imidazol-2-yl)-2-methylpyrrolidin-1-yl) (5 Methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone)

2. Act-541468

3. Daridorexant

4. Methanone, ((2s)-2-(6-chloro-7-methyl-1h-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2h-1,2,3-traizol-2-yl)phenyl)-

2.3.2 Depositor-Supplied Synonyms

1. Daridorexant

2. 1505484-82-1

3. Act-541468

4. Quviviq

5. Daridorexant [usan]

6. Lmq24g57e9

7. Act541468

8. [(2~{s})-2-(6-chloranyl-7-methyl-1~{h}-benzimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-methoxy-2-(1,2,3-triazol-2-yl)phenyl]methanone

9. [(2s)-2-(5-chloro-4-methyl-1h-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone

10. [(2s)-2-(5-chloro-4-methyl-1h-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl][5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl]methanone

11. Methanone, ((2s)-2-(6-chloro-7-methyl-1h-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)-

12. Nemorexant (former Name)

13. Daridorexant [inn]

14. Unii-lmq24g57e9

15. Daridorexant [who-dd]

16. Chembl4297590

17. Schembl16766318

18. Gtpl11648

19. Bdbm334973

20. Dtxsid701336356

21. Nemorexant; Act-541468

22. Who 10679

23. Us9732075, Example 5.36

24. At32805

25. Db15031

26. Hy-109095

27. Cs-0039396

28. Act 541468;act-541468

29. (2s)-2-(5-chloro-4-methyl-1h-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone

30. (s)-(2-(5-chloro-4-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5 Methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone

31. (s)-2-(5-chloro-4-methyl-1h Benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl](5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone

32. [(s)-2-(5-chloro-4-methyl-1h-benzoimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone

2.4 Create Date

2015-06-22

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₂₃ClN₆O₂
Molecular Weight	450.9 g/mol
XLogP3	4.1
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	4
Exact Mass	450.1571017 g/mol
Monoisotopic Mass	450.1571017 g/mol
Topological Polar Surface Area	88.9 Å²
Heavy Atom Count	32
Formal Charge	0
Complexity	693
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

5 Pharmacology and Biochemistry

5.1 FDA Pharmacological Classification

5.1.1 Active Moiety

DARIDOREXANT

5.1.2 FDA UNII

LMQ24G57E9

5.1.3 Pharmacological Classes

Orexin Receptor Antagonists [MoA]; Orexin Receptor Antagonist [EPC]

5.2 ATC Code

N05